AIQ's treatment response reports enhance your understanding of pharmacodynamics with precise spatiotemporal lesion analytics.
Discover how AIQ assesses treatment response using heterogeneity.
AIQ's medical device technology platform allows pharmaceutical companies to evaluate novel therapies faster and with fewer patients, reducing costs and expediting clinical trials. Our technology quantifies intra-patient heterogeneity of treatment response, which drives clinical outcomes.
Early quantification of lesion heterogeneity in pharmacodynamic effects, strongly correlates to overall response.
Quantification of individual lesion treatment response enables statistically significant data with a smaller sample size.
Spatial information enables biopsy of resistant and responding lesions to understand biological drivers of resistance.
Pilot studies can compare permutations of sequence and combination therapies before committing to a larger study.
AIQ’s workflow is simple and easy to implement with no interruptions. We pride ourselves on collaborative relationships that work more as partnerships. These workflows work whether you are running a single or multi-site study. We also partner with CROs to acquire the imaging data.
This document contains claims that have not been reviewed by the FDA. For information about applications in commercial distribution for patient management, see www.aiq-solutions.com/customers/hospitals